Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Keshav Panday (NPI 1710171194)

Field	Value
Entity Type	Individual
Organization	Keshav Panday
Address	1701 Renaissance Blvd Ste 110
City	Edmond
State	OK
ZIP	73013
Taxonomy	Specialist
NPI Enumerated	August 29, 2007

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only billing entity: lifetime Medicare revenue is $3.3M while Medicaid revenue is listed as none, so analyses and benchmarking should be interpreted in the context of a single dominant payer rather than a dual-payer mix. That concentration implies payer-specific policy changes (Medicare reimbursement, utilization edits, or drug coverage rules) will disproportionately affect overall revenue.

Revenue is highly concentrated in biologic infusion codes: the precomputed top-3 Medicare codes together account for 54.9% of this provider's total Medicare revenue, led by J1745 ($680.9K, 21.1%), J0129 ($557.7K, 17.2%), and J1602 ($537.7K, 16.6%). These three codes alone generate more than half of Medicare receipts, indicating the business is driven by a small number of high-volume drug administrations.

The code mix points to an infusion/biologics-specialty operation with ancillary chemotherapy and infusion services. High-revenue drug codes such as J1745 (infliximab), J0129 (abatacept), J1602 (golimumab), along with frequent administrations of J3262 (tocilizumab) and immune globulin codes (J1569, J1459), and chemotherapy administration codes 96413 and add-on 96415, indicate an outpatient infusion suite that bills both biologic agents and selected chemotherapy/infusion procedures.

The provider is a clear national outlier on several individual codes but modest in absolute Medicare scale: J1745 ranks #7 of 1352 providers nationally (100th percentile; extreme outlier), signaling unusually high national volume for infliximab. J1602 ranks #40 of 1041 (96th percentile; notably above typical national volume), while J0129 sits at #199 of 1221 (84th percentile; typical, unremarkable volume). Despite these dominant positions on specific drugs, total Medicare revenue of $3.3M places the practice at a modest overall revenue scale.

Multiple administration and infusion codes are also outliers, underscoring operational emphasis on throughput: 96375 ranks #60 of 5191 (99th percentile; extreme outlier) and 96415 ranks #48 of 4959 (99th percentile; extreme outlier), while 96365 and 96413 are in the high percentiles (97th). These high-ranking administration codes, combined with very large claim counts for low-unit-price drug codes, imply the practice bills many discrete infusion events.

The provider’s volume profile is weighted toward very high claim counts with low average paid-per-claim on several drugs, consistent with high-frequency, low-unit-dose billing patterns: J3262 shows 61.8K claims at $4 avg paid/claim, J1602 has 53.8K claims at $10 avg paid/claim, and J1745 has 26.2K claims at $26 avg paid/claim. This suggests revenue is generated by scale of administrations rather than by a small set of high-price single administrations.

Operational tenure and specialty: the NPI was enumerated on 2007-08-29 (~19 years ago) and taxonomy is Specialist, indicating a long-tenured specialist practice likely established in the outpatient infusion/biologic therapy space. That longevity supports the observed high cumulative claim volumes and repeat administration patterns.

From a payer-risk and competitive standpoint, reliance on a narrow set of biologic drug codes creates vulnerability to clinical or commercial shifts: large share from J1745 and other branded biologics means changes such as increased biosimilar substitution, step-therapy policies, or national price edits could materially reduce revenue. At the same time, the provider’s national-ranking strength on select codes (several labeled extreme outlier or notably above typical) indicates a competitive operational capability in delivering high-volume infusions relative to most peers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

56 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1745	Injection, infliximab, excludes biosimilar, 10 mg	26,190	$30	$680.9K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	16,900	$30	$557.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	53,770	$10	$537.7K
J0490	Injection, belimumab, 10 mg	7,270	$40	$269.1K
J3262	Injection, tocilizumab, 1 mg	61,760	$1	$247K
J9312	Injection, rituximab, 10 mg	2,400	$60	$141.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,040	$40	$141.4K
J0491	Injection, anifrolumab-fnia, 1 mg	10,800	$10	$129.6K
J3111	Injection, romosozumab-aqqg, 1 mg	15,120	$10	$121K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,740	$40	$98.6K

Showing 1–10 of 56

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

Keshav Panday — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

56 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	7	10	16,680	$30	$661.9K
J0490	3	10	8,730	$40	$562.9K
J3262	6	10	82,050	$1	$432.8K
J1602	5	20	25,400	$10	$412.3K
J1745	3	10	6,400	$30	$312.2K
J9312	6	10	3,650	$60	$246.8K
J0491	3	10	13,510	$10	$229.2K
J3111	13	20	22,470	$10	$216.7K
J1459	3	10	3,380	$40	$150.3K
J1569	7	20	3,670	$30	$125.8K

Showing 1–10 of 56

Related Providers

Other providers that share a Tax Identification Number (TIN) with Keshav Panday, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oklahoma Arthritis Center, P.C.	OK	Rheumatology Physician	$0	$10.1M
Craig Carson	OK	Rheumatology Physician	$9.7M	$0
Ana Kumar	OK	Rheumatology Physician	$4.1M	$0
Midwest City Hma Physician Management, LLC	OK	Obstetrics & Gynecology Physician	$0	$2.4M
Graciela Gallardo	OK	Family Medicine Physician	$710K	$0
Asim Chohan	OK	Cardiovascular Disease Physician	$564.9K	$0
Jeremy Morgan	OK	Family Nurse Practitioner	$509.6K	$0
Spencer Wopart	OK	Nurse Practitioner	$379.2K	$0
Patrick O'neill	OK	Family Medicine Physician	$347.3K	$0
Muzaffar Saleemi	OK	Family Medicine Physician	$277.7K	$0

Nearby Providers

Other providers in the same ZIP code as Keshav Panday, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Specialty Care Pediatrics, Inc.	OK	Home Health Agency	$0	$44.8M
Medical Resource Management, LLC	OK	Urgent Care Clinic/Center	$0	$14.9M
Sand Lily Healthcare, Inc.	OK	In Home Supportive Care Agency	$0	$8.9M
Christopher Fisher	OK	Internal Medicine Physician	$7.6M	$0
Summit Medical Center	OK	General Acute Care Hospital	$0	$7.1M
Brian Phelps	OK	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Sandeep Shah	OK	Retina Specialist (Ophthalmology) Physician	$3.9M	$0
Ryan Ridges	OK	Retina Specialist (Ophthalmology) Physician	$3.6M	$0
Michael Hood	OK	Retina Specialist (Ophthalmology) Physician	$3.5M	$0
Pathways Professional Counseling LLC	OK	Community/Behavioral Health Agency	$0	$3.4M

Keshav Panday — Billing Profile & Reimbursement Data

Sign up for Keshav Panday — Billing Profile & Reimbursement Data policy alerts

Keshav Panday — Billing Profile & Reimbursement Data

Sign up for Keshav Panday — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References